[HTML][HTML] Acquired Hemophilia A: An update on the etiopathogenesis, diagnosis, and treatment

E Zanon - Diagnostics, 2023 - mdpi.com
Acquired haemophilia A (AHA) is a rare bleeding disorder caused by inhibitory
autoantibodies against coagulation factor VIII (FVIII). AHA is a disease that most commonly …

[HTML][HTML] Emicizumab in acquired hemophilia A: Pros and cons of a new approach to the prevention and treatment of bleeding

S Pasca, E Zanon, PM Mannucci, F Peyvandi - Blood Transfusion, 2023 - ncbi.nlm.nih.gov
Emicizumab, a monoclonal bispecific antibody that mimics the function of activated factor VIII
(FVIII), is currently licensed for prophylactic use in patients with congenital hemophilia A with …

Emicizumab for acquired haemophilia A: A case series

MM Engelen, J Vandesande, J De Bent… - …, 2023 - Wiley Online Library
Background Emicizumab is approved to prevent bleeding in patients with congenital
haemophilia A with or without inhibitors. However, no randomized trials addressed the …

[HTML][HTML] Acquired Hemophilia A: Bleeding Pattern and Hemostatic Therapeutic Strategies

R Marino - Medicina, 2023 - mdpi.com
Acquired Hemophilia A (AHA) is a rare autoimmune disorder characterized by the onset of a
sudden and unexpected bleeding episode in a patient with no personal or family history of …

L'hémophilie A acquise: savoir y penser

S Desage, C Nougier - Revue Francophone des Laboratoires, 2024 - Elsevier
Résumé L'hémophilie A acquise (HAA) est un trouble hémorragique rare potentiellement
grave provoqué par l'apparition d'anticorps dirigés contre le facteur VIII (FVIII). Elle est le …

[HTML][HTML] Acquired hemophilia A (and other acquired coagulation factor inhibitors)

P James - medilib.ir
INTRODUCTION—Acquired clotting factor inhibitors are autoantibodies that either inhibit the
activity or increase the clearance of a clotting factor. These patients often present with …